Our take
Myomo is the clearest medical robotics business in this group to understand from the outside. Its MyoPro brace reads weak muscle signals in a paralyzed arm and powers the elbow and hand, Medicare publishes what it pays for the device, and the company reports orders, average selling price, and patient pipeline every quarter.6,5,3
It is still small and unprofitable. Revenue was $40.9 million in 2025, and Myomo expects $45 million to $47 million in 2026. It had $13.5 million in cash and short-term investments at June 30, 2026.4,3
Scores by criterion
Each criterion is defined on our methodology page.
Who uses Myomo and what it's for
MyoPro is prescribed for people with weakness or partial paralysis in the arm and hand after a stroke, brachial plexus injury, or other neuromuscular condition.1,6 It is referred at rehabilitation centers including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Kennedy Krieger Institute, and twenty Veterans Affairs hospitals.2
The buyer is usually an insurer. Myomo says it has in-network access to more than 100 million covered lives, including Medicare and VA patients, and in 2026 added state contracts with Anthem Blue Cross Blue Shield plans.3
A brace driven by the wearer’s own muscle signals
When the wearer tries to move, sensors in the brace detect the weak muscle signal and a motor moves the arm in that direction, so the person controls the motion. Myomo says this lets users feed themselves, carry objects, and do household tasks.6
The technology came from MIT and Harvard Medical School research. Myomo licensed MIT's patents in 2006, and its first robotic elbow brace received FDA approval in 2007.6,7
Orders and referrals reported each quarter
In the second quarter of 2026 Myomo booked a record 255 orders, added 739 patients to its pipeline, and reported an average selling price of about $55,500. Revenue rose 21% to $11.7 million while operating expenses grew less than 1%.3
More than half of that quarter's revenue came from recurring sources such as clinician referrals, orthotic and prosthetic partners, and the VA. A randomized controlled trial at the University of Utah had enrolled 25 of a planned 50 subjects.3
Second quarter 2026 revenue was $11.7 million, up 21% from a year earlier, with a gross margin of 72.1%. Myomo guided third quarter revenue to $11.5 million to $12.0 million, up 14% to 19%, and expects cash burn below $2 million in the second half of 2026.11,12
On November 9, 2026 Myomo reported record third quarter revenue of $12.3 million, up 22% from a year earlier, on 222 MyoPro units at an average selling price of about $55,500. Gross margin rose to 71.3%, orders reached a record 258, recurring patient sources made up 54% of revenue, and Adjusted EBITDA was about breakeven (a loss of $1,513). The net loss was $4.2 million, including a $1.8 million non-cash charge, cash and short-term investments were $11.9 million, and the University of Utah trial had enrolled 35 of a planned 50 subjects. Myomo narrowed full-year 2026 revenue guidance to $46 million to $47 million.30
Prices set by Medicare
The Centers for Medicare and Medicaid Services set fee schedule rates of $33,480.90 for the MyoPro Motion W and $65,871.74 for the Motion G, effective April 1, 2024.5 Because private insurers and the VA negotiate their own rates, the average selling price Myomo reports is the best guide to what the device brings in.3
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where Myomo wins or loses |
|---|---|---|---|---|
| Myomo | MyoPro powered arm and hand brace1 | Medicare fee schedule rates of $33,481 and $65,8725 | Patients reached through clinician referrals and orthotics and prosthetics channels3,4 | Published Medicare rate and quarterly reporting; small, unprofitable company |
| Kandu | FDA-cleared brain-computer interface for at-home stroke therapy13 | Prescription device billed under HCPCS E0738 as a Medicare capped rental13 | Chronic stroke survivors at least six months post-stroke13 | IpsiHand wins as a therapy device for stroke recovery at home. MyoPro wins for patients who need powered help with daily arm use and for conditions beyond stroke. |
| Vivistim | Implanted vagus nerve stimulator paired with rehabilitation14 | Not published14 | FDA approved for upper limb recovery after ischemic stroke14 | Vivistim wins for patients who want therapy gains without wearing a device. MyoPro wins by avoiding surgery. |
| Cyberdyne | Medical HAL wearable robot driven by the wearer's bioelectric signals18 | Not published; mainly rentals and treatment services19 | Approvals or certifications in more than 20 countries27 | Myomo wins for arm and hand weakness. Cyberdyne wins for patients relearning to walk. |
| Ekso Bionics | EksoNR exoskeleton for gait training after stroke and brain injury21 | Not published21 | Inpatient rehabilitation facilities; first exoskeleton FDA-cleared for stroke21 | Ekso wins for walking practice in the clinic. MyoPro wins for daily arm and hand use at home. |
| Lifeward | ReWalk personal exoskeleton and AlterG anti-gravity systems23 | Medicare fee of $91,032 for a personal exoskeleton22 | Individual users through Medicare and insurers; AlterG in more than 4,000 facilities22 | Lifeward wins on walking for people with spinal cord injury. Myomo wins on arm and hand function. |
| Wandercraft | Atalante X and Eve self-balancing exoskeletons28 | Not published28 | Devices in more than 700 rehabilitation centers after buying Ekso29 | Myomo wins for arm and hand weakness. Wandercraft wins for people who need help to stand and walk. |
Limits
Every unit has to be prescribed, custom fitted by a trained clinician, and approved by an insurer, which slows adoption and makes the path to a device longer than a typical purchase.2,3
Losses continue. Myomo reported a net loss of $4.0 million in the second quarter of 2026, including a $1.2 million non-cash charge.3
Guidance has moved around. In 2025 Myomo lowered its full-year revenue guidance to $40 million to $42 million and reported a wider second-quarter loss, and AInvest reported that its shares fell about 9% in a September 17, 2025, session after those results. In 2026 it raised guidance.10,3
What customers say
Where it helps
It’s giving me a sense of self-sufficiency, and to me, that’s pride.
Myomo also points to published clinical research showing an immediate, clinically significant reduction in upper extremity impairment with MyoPro.2
Where it falls short
We found no independent patient reviews to quote. The drawbacks in public material are insurance approval, the fitting process, and the company's continued losses.3
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: Myomo financial results, Medicare fee schedule announcement, and patient stories.
Leadership

Paul R. Gudonis
Chairman and chief executive officerGudonis has led Myomo since 2011. He previously ran Genuity and Centra Software and helped introduce AT&T's first cellular service.15



Sources
- Myomo, Homepage, accessed November 3, 2026
- Myomo, About us, accessed November 3, 2026
- Myomo, Second quarter 2026 results, SEC exhibit 99.1, August 5, 2026, accessed November 3, 2026
- Myomo, Fourth quarter and full year 2025 results, accessed November 3, 2026
- Myomo, CMS posts final Medicare DMEPOS fee schedule rate for the MyoPro, March 1, 2024, accessed November 3, 2026
- Myomo, Myomo launches initial public offering via JOBS Act Regulation A+, March 15, 2017, accessed November 3, 2026
- AUTM Better World Project, Myomo e100 NeuroRobotic System, accessed November 3, 2026
- Myomo, Prospectus filed with the SEC, 2020, accessed November 3, 2026
- Myomo, Management, accessed November 3, 2026
- AInvest, Myomo (MYO) shares plunge 9.09% as revised 2025 forecast and wider Q2 losses spur investor fears, September 17, 2025, accessed November 3, 2026
- Business Wire via Yahoo Finance, Myomo reports second quarter 2026 financial and operating results, August 5, 2026, accessed November 3, 2026
- Myomo, Myomo to report third quarter 2026 financial results on November 9, November 2, 2026, accessed November 10, 2026
- Neurolutions, For clinicians, accessed November 3, 2026
- Vivistim, Homepage, accessed November 3, 2026
- Myomo, Paul Gudonis leadership profile, accessed November 3, 2026
- Neurolutions, Homepage, accessed November 6, 2026
- Neurolutions, Merger announcement, accessed November 6, 2026
- Cyberdyne, Medical HAL lower limb type, accessed November 2, 2026
- Cyberdyne, Financial results briefing for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
- Cyberdyne, Consolidated financial results for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
- Ekso Bionics, EksoNR, accessed November 1, 2026
- Lifeward, Form 10-Q for the quarter ended September 30, 2024, accessed November 1, 2026
- Lifeward, Fourth quarter and full year 2025 financial results, accessed November 1, 2026
- Wandercraft, Atalante X, accessed November 1, 2026
- Wandercraft, Eve personal exoskeleton, accessed November 1, 2026
- Wandercraft, Wandercraft acquires Ekso Bionics, accessed November 1, 2026
- Cyberdyne, About Cyberdyne, accessed November 3, 2026
- Wandercraft, Homepage, accessed November 2, 2026
- IZON, Wandercraft acquires Ekso Bionics to form major exoskeleton player, accessed November 2, 2026
- Myomo, Third quarter 2026 results, SEC exhibit 99.1, November 9, 2026, accessed November 10, 2026


